High serum 25(OH)D linked to lower breast cancer mortality

High serum 25(OH)D linked to lower breast cancer mortality

(HealthDay)—Higher concentrations of serum 25-hydroxyvitamin D (25[OH]D) are associated with lower mortality from breast cancer, according to a meta-analysis published in the March issue of Anticancer Research.

Sharif B. Mohr, M.P.H., from the Naval Health Research Center in San Diego, and colleagues conducted a meta-analysis of five studies to examine the correlation between 25(OH)D at diagnosis and mortality from breast cancer. A random-effects model was used to calculate hazard ratios.

The researchers observed a correlation between higher 25(OH)D concentration and lower case-fatality rates after breast cancer diagnosis. Compared with patients in the lowest quintile of 25(OH)D, those in the highest quintile had about half the death rate from breast cancer (hazard ratio, 0.56).

"High serum 25(OH)D was associated with lower from breast cancer. Serum 25(OH)D in all patients with should be restored to the normal range (30 to 80 ng/mL), with appropriate monitoring," the authors write. "Clinical or field studies should be initiated to confirm that this association was not due to reverse causation."

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

Vitamin D increases breast cancer patient survival

Mar 06, 2014

Breast cancer patients with high levels of vitamin D in their blood are twice as likely to survive the disease as women with low levels of this nutrient, report University of California, San Diego School of Medicine researchers ...

CDC: breast cancer mortality higher in black women

Nov 15, 2012

(HealthDay)—With earlier detection and better treatment, the mortality rate from breast cancer has fallen over the last two decades; black women, however, still die from the disease at a disproportionately ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.